Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMALDH1A1HSD17B10KDM4E | |
| SCHEMBL3661080 | 0.84 | CA12 (0.42) | SMN1; SMN2ALDH1A1HSD17B10KDM4ETP53 | |
| Hydrochloric Acid SCHEMBL11303697 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2PKMALDH1A1HSD17B10KDM4E | |
| SCHEMBL8597983 | 0.83 | TGM2 (0.49) | SMN1; SMN2PKMALDH1A1KDM4ETP53 | |
| SCHEMBL16166446 | 0.82 | GRK2 (0.43) | SMN1; SMN2PKMALDH1A1KDM4EPOLB | |
| SCHEMBL16166407 | 0.81 | PRSS1 (0.46) | — | |
| SCHEMBL7335880 | 0.80 | POLB (0.51) | SMN1; SMN2ALDH1A1TP53HPGDPOLB | |
| SCHEMBL7346083 | 0.79 | MAPT (0.54) | SMN1; SMN2ALDH1A1HSD17B10KDM4ETP53 | |
| SCHEMBL1372423 | 0.78 | POLB (0.63) | ALDH1A1HSD17B10KDM4ETP53HPGD | |
| SCHEMBL18740426 | 0.78 | PKM (0.47) | SMN1; SMN2PKMALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1005356-B1 | NOVEL ANTIBACTERIAL AGENTS | THERAVANCE INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1005356-A4 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-1999064049-A9 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-1005356-A1 | NOVEL ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999064049-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0089752-B1 | FLUORAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN RECORDING SYSTEMS | KANZAKI PAPER MANUFACTURING CO., LTD (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4524373-A | Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1985-06-18 | — | — | US | disclosed |
| EP-0089752-A2 | Fluoran derivatives, process for their preparation and their use in recording systems | KANZAKI PAPER MANUFACTURING CO., LTD (JP) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | SMN1; SMN2 4850/4885PKM 3756/4885ALDH1A1 1953/4885 |
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | SMN1; SMN2 4852/4885PKM 3360/4885ALDH1A1 2244/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | SMN1; SMN2 4852/4885PKM 3360/4885ALDH1A1 2244/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | SMN1; SMN2 4852/4885PKM 3360/4885ALDH1A1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.